Alaunos Therapeutics, Inc. TCRT 深 沪
等待开盘 10-14 09:30:00 美东时间
3.4977
+2.448
+233.11%
华盛通- 最 高4.32
- 今 开1.75
- 成交量 1.89亿股
- 最 低 1.51
- 昨 收 1.05
- 总市值 888.58万
- 52周最高 4.50
- 市盈率 静 --
- 换手率 7453.04%
- 52周最低 0.719
- 委 比 41.54%
- 总股本 254.05万
- 历史最高 2239.50
- 量 比 502.23
- 振 幅 267.62%
- 历史最低 0.719
- 每 手 1
- 风险率 0.74%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Alaunos Therapeutics (TCRT) Stock Soars Over 29% After-Hours: Here's What's Going On
Alaunos Therapeutics Inc. (NASDAQ:TCRT) shares climbed 29.28% to $2.07 after the bell on Thursday following a Securities and Exchange Commission filing that showed the company approved and adopted its Second Amended and Restated By-Laws, effective immediately. Bylaws Overhaul Lowers the Bar for Shar...
09-18 14:30
美股夜盘 | Alaunos Therapeutics, Inc.暴升31.25%，最新股价2.1美元
Alaunos Therapeutics, Inc.暴升31.25%，报2.1美元
09-18 08:01
Alaunos’ ALN1003 Shows Statistically Significant Reduction In Liver Weight Independent Of Body Fat In Preclinical Analysis
This statistical finding supports a lower liver-weight signal after adjustment for body fat percentage, suggesting the finding was not fully explained by measured body fat in this model Liver-weight findings are directionally consistent with previously disclosed data on lower liver injury enzymes, l...
06-29 20:36
Alaunos Therapeutics Reports Preclinical Results For ALN1003 Showing Weight Loss, Improved Insulin Sensitivity, And Better Liver Health In Obese Mouse Studies
ALN1003 demonstrated consistent, favorable effects across key drivers of metabolic disease, including reductions in body weight and fat mass, improved insulin sensitivity, enhanced adipose function, and improved liver
05-26 23:05
Alaunos Therapeutics Issues Updated Preclinical Data From Non-GLP Diet-Induced Obesity Mouse Studies Evaluating ALN1003, Investigational Oral Metabolic Therapeutic Candidate
Alaunos Therapeutics, Inc. (NASDAQ:TCRT) today announced updated preclinical data from non-GLP diet-induced obesity (DIO) mouse studies evaluating ALN1003, the Company's investigational oral metabolic therapeutic
05-18 20:09
Valion Bio Appoints Melinda Lackey as General Counsel
Seasoned Biopharmaceutical Attorney with Deep IP, Clinical-Stage, and Nasdaq Public Company Experience Joins Leadership Team SAN ANTONIO, May 4, 2026 /PRNewswire/ -- Valion Bio, Inc. (former...
05-05 04:05
Alaunos Therapeutics Announces Early Data From Two Non-GLP DIO Mouse Studies Evaluating ALN1003 For Treating Obesity And Related Conditions
The lead drug candidate, ALN1003, showed dose-related body weight loss and favorable body composition changes in the DIO mouse modelALN1003 also demonstrated reductions in liver weight and improvements in select
03-02 19:37
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Bluejay Diagnostics (NASDAQ:BJDX) shares rose 113.4% to $3.99 during T...
2025-10-09 20:07
Why Richardson Electronics Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket
Shares of Richardson Electronics, Ltd. (NASDAQ:RELL) rose sharply in pre-market...
2025-10-09 17:12
4 Biotech Stocks That Are Showing Weakness: Momentum Scores Fading Over The Past Week
Several biotech stocks have seen their strength fade over the past week, with their Momentum scores in Benzinga's Edge Stock Rankings witnessing a significant decline.
2025-09-03 18:21
